To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
The Service Hospitalier Frédéric Joliot (SHFJ), directed by Vincent Lebon, is a molecular and functional imaging center located on the Orsay hospital site. It ensures a medical service mission and a research and development mission which are mainly in the three following disciplines: oncology, neurology and pharmacology. This research aims to create new imaging tools to improve the diagnosis and evaluation of innovative therapies.
BioMaps researchers compared the diagnostic performance of the rabbit visual pattern observed in 18F-DOPA PET imaging with the standard procedure approved by the international nuclear imaging societies for the diagnosis of parkinsonian syndromes in PET/MRI and obtained encouraging results, which may validate the clinical utility of such a model
Researchers from the SHFJ laboratory at ISMO have demonstrated the value of platinum nanoparticles as potential radiosensitizing agents for radiation therapy.
Researchers from the BioMaps laboratory (SHFJ) and the Molecular Engineering for Health Service (SIMoS, DMTS) developed an enzymatic approach for radiofluorination of an anti-PD-L1 Fab and compared its in vivo properties to the same Fab stochastically labeled by two conventional methods.
Researchers from the SHFJ, in collaboration with NeuroSpin, show that the use of focused ultrasound does not increase the therapeutic effects of cetuximab on glioblastoma although the opening of the blood-brain barrier is transiently effective.
Radiochemists from the BioMaps unit (SHFJ) have developed and automated the synthesis of an 18F-fluoropyridine containing a thiol function (-SH), allowing its conjugation to model biomolecules within 45 minutes. A step towards rapid radiolabeling of complex biological molecules for PET imaging.
Researchers from the SHFJ and the DMTS have developed optimized radioligands for immunoPET imaging. The objective is to better predict the effectiveness of anti-PD1/anti-PDL1 immunotherapy used to fight certain cancers.
A team from BioMaps (SHFJ), in collaboration with several hospital groups, shows that hybrid PET/MRI imaging significantly improves the detection of epileptogenic foci and, consequently, the outcome of surgical treatment of epilepsy.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.